Zurich Cantonal Bank
ABUS icon

Zurich Cantonal Bank’s Arbutus Biopharma ABUS Stock Holding History

Zurich Cantonal Bank’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$265K Sell
55,233
-70,000
-56% -$307K ﹤0.01% 2234
2026
Q1 		$564K Sell
125,233
-3,082
-2% -$13.5K ﹤0.01% 1775
2025
Q4 		$617K Buy
128,315
+27,977
+28% +$126K ﹤0.01% 1656
2025
Q3 		$456K Hold
100,338
– – ﹤0.01% 1791
2025
Q2 		$310K Buy
100,338
+16,175
+19% +$53.7K ﹤0.01% 1940
2025
Q1 		$294K Sell
84,163
-5,502
-6% -$18.3K ﹤0.01% 1900
2024
Q4 		$293K Buy
89,665
+52,162
+139% +$192K ﹤0.01% 1957
2024
Q3 		$144K Buy
37,503
+30,723
+453% +$118K ﹤0.01% 2277
2024
Q2 		$20.9K Sell
6,780
-101
-1% -$303 ﹤0.01% 2588
2024
Q1 		$17.8K Buy
+6,881
New +$17.8K ﹤0.01% 2635
2023
Q1 		– Sell
-6,178
Closed -$14.4K – 2856
2022
Q4 		$14.4K Sell
6,178
-1,185
-16% -$2.83K ﹤0.01% 2786
2022
Q3 		$14K Hold
7,363
– – ﹤0.01% 2841
2022
Q2 		$20K Sell
7,363
-745
-9% -$1.91K ﹤0.01% 2795
2022
Q1 		$24K Buy
+8,108
New +$24.8K ﹤0.01% 2647

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Zurich Cantonal Bank's ABUS Position: Q2 2026 in Review

Zurich Cantonal Bank reduced its Arbutus Biopharma (ABUS) stake by 56% in Q2 2026, selling an estimated $307K and leaving 55,233 shares worth $265K. The position accounts for ﹤0.01% of the portfolio, ranked #2234.

Zurich Cantonal Bank first reported a position in ABUS in Q1 2022 and has held it in 14 quarters since. The position peaked at $617K in Q4 2025. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Zurich Cantonal Bank held 55,233 shares of Arbutus Biopharma worth $265K as of Q2 2026.
  • Zurich Cantonal Bank sold 70,000 Arbutus Biopharma shares in Q2 2026, an estimated $307K.
  • Arbutus Biopharma made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2234 holding.
  • Zurich Cantonal Bank first reported a position in Arbutus Biopharma in Q1 2022 and has held it in 14 quarters since.
  • Zurich Cantonal Bank's Arbutus Biopharma position peaked at $617K in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.